BCEL insider filings
Atreca, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-04-17. Screen BCEL transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for BCEL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Atreca, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-04-17 | 4 | Orwin John A — PRESIDENT & CEO, Director | Purchase (P): 1 @ $0.01 | EDGAR |
| 2024-04-03 | 4 | Courtney Phillips — GENERAL COUNSEL & SECRETARY | Sale (S): 7,061 @ $0.37 | EDGAR |
| 2024-04-03 | 4 | Orwin John A — PRESIDENT & CEO, Director | Sale (S): 22,951 @ $0.37 | EDGAR |
| 2024-04-03 | 4 | Serafini Tito — Director | Sale (S): 20,788 @ $0.07 | EDGAR |
| 2024-04-03 | 4 | Serafini Tito — Director | Sale (S): 8,393 @ $0.37 | EDGAR |
| 2023-10-23 | 4 | BAKER BROS. ADVISORS LP BAKER JULIAN BAKER FELIX Baker Bros. Advisors (GP) LLC | Sale (S): 22,837 @ $0.40 · Sale (S): 251,902 @ $0.40 | EDGAR |
| 2023-08-04 | 4 | Gould Stephen E — Chief Scientific Officer | Sale (S): 4,076 @ $0.95 | EDGAR |
| 2023-08-04 | 4 | Courtney Phillips — General Counsel & Secretary | Sale (S): 4,076 @ $0.95 | EDGAR |
| 2023-08-04 | 4 | Serafini Tito — Chief Strategy Officer, Director | Sale (S): 5,487 @ $0.95 | EDGAR |
| 2023-08-04 | 4 | CROSS HERB — Chief Financial Officer | Sale (S): 5,487 @ $0.95 | EDGAR |
| 2023-06-15 | 4 | Rolfe Lindsey — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Robinson William Hewitt — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Ma Stacey — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Lacey David L. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Brady Stephen R — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | BERGER FRANKLIN M — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | BALL KRISTINE M — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | Courtney Phillips — General Counsel & Secretary | Grant/award (A): 32,500 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | Gould Stephen E — Chief Scientific Officer | Grant/award (A): 32,500 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | Orwin John A — President & CEO, Director | Grant/award (A): 435,000 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | Serafini Tito — Chief Strategy Officer, Director | Grant/award (A): 43,750 @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2023-02-13 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 43,750 @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Bishop Philippe C — Chief Medical Officer | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | Courtney Phillips — General Counsel & Secretary | Sale (S): 6,432 @ $1.78 | EDGAR |
| 2022-09-20 | 4 | Orwin John A — President & CEO, Director | Sale (S): 20,908 @ $1.78 | EDGAR |
| 2022-09-20 | 4 | Serafini Tito — Chief Strategy Officer, Director | Sale (S): 7,646 @ $1.78 | EDGAR |
| 2022-09-20 | 4 | CROSS HERB — Chief Financial Officer | Sale (S): 7,646 @ $1.78 | EDGAR |
| 2022-06-30 | 4 | Serafini Tito — Chief Strategy Officer, Director | Sale (S): 15,000 @ $2.02 | EDGAR |
| 2022-06-17 | 4 | Gould Stephen E — Chief Scientific Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Courtney Phillips — General Counsel & Secretary | Grant/award (A): 80,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) @ $0 · Grant/award (A): 45,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) @ $0 · Grant/award (A): 91,666 (derivative) · Disposition to issuer (D): 91,666 (derivative) @ $0 · +2 more | EDGAR |
| 2022-06-15 | 4 | Orwin John A — President & CEO, Director | Grant/award (A): 260,000 (derivative) · Disposition to issuer (D): 260,000 (derivative) @ $0 · Grant/award (A): 241,000 (derivative) · Disposition to issuer (D): 241,000 (derivative) @ $0 · Grant/award (A): 148,754 (derivative) · Disposition to issuer (D): 148,754 (derivative) @ $0 · +2 more | EDGAR |
| 2022-06-15 | 4 | Serafini Tito — Chief Strategy Officer, Director | Grant/award (A): 95,000 (derivative) · Disposition to issuer (D): 95,000 (derivative) @ $0 · Grant/award (A): 88,000 (derivative) · Disposition to issuer (D): 88,000 (derivative) @ $0 · Grant/award (A): 141,395 (derivative) · Disposition to issuer (D): 141,395 (derivative) @ $0 · +2 more | EDGAR |
| 2022-06-15 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 95,000 (derivative) · Disposition to issuer (D): 95,000 (derivative) @ $0 · Grant/award (A): 224,999 (derivative) · Disposition to issuer (D): 224,999 (derivative) @ $0 · Grant/award (A): 97,000 (derivative) · Disposition to issuer (D): 97,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Brady Stephen R — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Lacey David L. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Ma Stacey — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Rolfe Lindsey — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Robinson William Hewitt — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | BERGER FRANKLIN M — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | BALL KRISTINE M — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-03-08 | 4 | Serafini Tito — Chief Strategy Officer, Director | Sale (S): 30,000 @ $5 | EDGAR |
| 2021-12-28 | 4 | Courtney Phillips — General Counsel & Secretary | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-12-28 | 4 | Orwin John A — President & CEO, Director | Grant/award (A): 260,000 (derivative) @ $0 | EDGAR |
| 2021-12-28 | 4 | Serafini Tito — Chief Strategy Officer, Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2021-12-28 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2021-09-28 | 4 | Serafini Tito — Chief Strategy Officer, Director | Gift (G): 50,000 @ $0 · Gift (G): 50,000 @ $0 · Sale (S): 30,000 @ $6.58 | EDGAR |
| 2021-09-13 | 4 | Serafini Tito — Chief Strategy Officer, Director | Grant/award (A): 42,200 @ $0 | EDGAR |
| 2021-09-13 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 42,200 @ $0 | EDGAR |
Recent 8-K events — Atreca, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-03-11 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-02-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-09-21 | 8-K | 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-09-14 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BCEL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs